A stage version of Khaled Hossein's 2003 novel The Kite Runner, which has been published in 70 countries, selling 31.5 million copies in 60 languages, is headed to the West End's Wyndham's Theatre.

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite Pharma, Inc. (Nasdaq:KITE) today announced new data presentations from multiple studies related to its lead investigational candidate, axicabtagene ...

AUSTIN – Each year, on the first Sunday in March, more than 20,000 locals gather on Zilker’s sprawling turf to fly kites, compete against fellow kite flyers in various categories, and to simply spend ...

Kite is still aiming to have a submission with FDA before the year is over, a timeline that would set it up to win approval for KTE-C19 next year. And with Juno thinking the data from its ongoing ...

CAR-T immunotherapy is one of the most resource-intensive and personalized therapies in clinical trials today. It can deliver astounding results, but the scalability and affordability of the therapy ...

Shares of Kite Pharma (NASDAQ: KITE), a clinical-stage biotechnology company focused on developing therapies based on chimeric antigen receptors (CARs) for the treatment of solid and blood cancers, ...

After years of anticipation, the world learned on Monday that Gilead Sciences Inc. will acquire Kite Pharma Inc. for almost $12 billion in cash. It’s an answer to the loud chorus of investors, ...

Kite fans prepare to set aloft a large-scale show kite during the Thailand International Kite Festival 2017 at Cha-Am Beach in Central Thailand's Phetchaburi province, on March 10, 2017. The Thailand ...

After Pfizer outbid Gilead for Medivation last September, Todd Hagopian named 4 companies Gilead might go after next. Kite Pharma, then trading at about $55, was among them. On Monday, Gilead proved ...

Shares of Kite Pharma, Inc.KITE have had an impressive run so far this year riding on the progress of its revolutionary CAR-T therapy so far this year. The biopharmaceutical company's shares have ...

Gilead Sciences agreed to buy Kite Pharma in a $11.9 billion deal on Monday, as it looks to fuel growth with an emerging class of cancer immunotherapies that are expected to generate billions. Gilead ...